Treatment Does Little to Prevent Hypertension and Microalbuminuria in Children with Diabetes

Published Online: Monday, July 22, 2013
Follow Pharmacy_Times:
Children with type 2 diabetes continue to develop hypertension and microalbuminuria at fast rates, regardless of treatment, according to the results of a study published in the June 2013 issue of Diabetes Care.
 
The study included nearly 700 overweight children from the TODAY clinical trial, an ongoing study on treatment of type 2 diabetes in children and adolescents. Children in the current study were aged between 10 and 17 and had been diagnosed with diabetes for less than 2 years. The participating children were randomly assigned to receive metformin, metformin plus rosiglitazone, or metformin plus lifestyle intervention.
 
At the start of the study, 11.6% of participants had hypertension. By the end of the study (average follow-up of 3.9 years), 33.8% had hypertension. In addition, the rate of microalbuminuria among participants increased from 6.3% at baseline to 16.6% at the end of the study. The researchers also observed that boys and those with higher BMIs were at significantly increased risk for hypertension. Risk of microalbuminuria was associated with poor glycemic control, but not with a particular gender or ethnicity.
 
The authors note that the progression of hypertension and microalbuminuria observed in children was faster than that typically seen in adults and stress the importance of obesity prevention starting at young ages.
 
 


Related Articles
In light of misrepresented statistics and overstated fears about statin-related adverse events, here are 3 of the biggest myths your patients may have heard about these life-saving medications—and the facts
Beyond working in traditional retail, community, and health-system settings, pharmacy students have a lot of options. Two Roosevelt University pharmacy students are proof of that.
Sanofi has announced the FDA approval of its insulin glargine injection (Toujeo), a once-daily long-acting basal insulin, for the improvement of glycemic control in adults with type 1 and type 2 diabetes.
Novo Nordisk has positive results from a completed phase 2 trial on the oral formulation of its investigational, long-acting human glucagon-like peptide-1 analogue.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$